IMMUNEERING CORP - CLASS A (IMRX) Forecast, Price Target & Analyst Ratings

NASDAQ:IMRX • US45254E1073

Current stock price

5.52 USD
-0.14 (-2.47%)
At close:
5.52 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMMUNEERING CORP - CLASS A (IMRX).

Forecast Snapshot

Consensus Price Target

Price Target
$17.34
+ 214.13% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$0.26
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$17.34
Upside
+ 214.13%
From current price of $5.52 to mean target of $17.34, Based on 12 analyst forecasts
Low
$11.11
Median
$14.79
High
$31.50

Price Target Revisions

1 Month
0.99%
3 Months
0.99%

Price Target Summary

12 Wall Street analysts provided a forecast for the next 12 months for IMRX. The average price target is 17.34 USD. This implies a price increase of 214.13% is expected in the next year compared to the current price of 5.52.
The average price target has been revised upward by 0.99% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

IMRX Current Analyst RatingIMRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

IMRX Historical Analyst RatingsIMRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.00%
IMRX was analyzed by 12 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IMRX.
In the previous month the buy percentage consensus was at a similar level.
IMRX was analyzed by 12 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-09NeedhamReiterate Buy -> Buy
2025-11-13Chardan CapitalMaintains Buy -> Buy
2025-10-31Leerink PartnersInitiate Outperform
2025-09-30HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-26Chardan CapitalMaintains Buy -> Buy
2025-09-25OppenheimerMaintains Outperform -> Outperform
2025-09-15NeedhamMaintains Buy -> Buy
2025-08-26NeedhamReiterate Buy -> Buy
2025-08-14Chardan CapitalMaintains Buy -> Buy
2025-06-18Chardan CapitalMaintains Buy -> Buy
2025-06-18MizuhoMaintains Outperform -> Outperform
2025-06-18NeedhamReiterate Buy -> Buy
2025-06-05NeedhamReiterate Buy -> Buy
2025-05-07OppenheimerMaintains Outperform -> Outperform
2025-05-06Chardan CapitalMaintains Buy -> Buy
2025-04-10NeedhamReiterate Buy -> Buy
2025-03-24Chardan CapitalMaintains Buy -> Buy
2025-03-21NeedhamReiterate Buy -> Buy
2025-02-06NeedhamReiterate Buy -> Buy
2025-01-13NeedhamReiterate Buy -> Buy
2025-01-08Chardan CapitalMaintains Buy -> Buy
2025-01-07NeedhamReiterate Buy -> Buy
2024-11-20Chardan CapitalMaintains Buy -> Buy
2024-11-14NeedhamReiterate Buy -> Buy
2024-09-13NeedhamReiterate Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$0.26
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
38.07%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
12.82%
EPS (3 Months)
27.14%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
IMRX revenue by date.IMRX revenue by date.
2.31M
20.31%		2.08M
-9.96%		320K
-84.62%
-100.00%		19.584M52.785M
169.53%		133.63M
153.16%		228.78M
71.20%		290.04M
26.78%		399.65M
37.79%		540.51M
35.25%
EBITDA
YoY % growth
IMRX ebitda by date.IMRX ebitda by date.
-17.06M
-171.66%		-33.84M
-98.36%		-51.46M
-52.07%		-59.355M
-12.83%		-66.372M
-9.57%		-79.028M
-24.23%		-89.405M
-13.13%		-133.518M
-49.34%		-168.606M
-26.28%		-177.48M
-5.26%		-121.89M
31.32%		4.59M
103.77%		224.6M
4,793.25%		N/A
EBIT
YoY % growth
IMRX ebit by date.IMRX ebit by date.
-17.08M
-171.11%		-33.89M
-98.42%		-51.74M
-52.67%		-58.458M
-12.90%		-65.416M
-9.56%		-68.597M
-7.18%		-89.167M
-29.99%		-99.501M
-11.59%		-94.687M
4.84%		-47.019M
50.34%		-7.322M
84.43%		-7.402M
-1.08%		110.74M
1,596.16%		231.29M
108.86%
Operating Margin
IMRX operating margin by date.IMRX operating margin by date.
-739.39%-1,629.33%-16,168.75%N/AN/AN/AN/A-508.07%-179.38%-35.19%-3.20%-2.55%27.71%42.79%
EPS
YoY % growth
IMRX eps by date.IMRX eps by date.
N/AN/A-1.92
43.61%		-1.88
1.56%		-1.91
-7.41%		-1.45
32.02%		-1.24
10.03%		-1.40
-12.60%		-1.14
18.23%		-1.13
1.25%		-0.59
47.89%		-0.44
25.44%		1.54
451.16%		3.59
133.11%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.26
38.07%		-0.29
26.69%		-0.34
11.42%		-0.38
-112.50%		-0.37
-41.18%		-0.42
-42.61%		-0.44
-30.30%		-0.46
-20.00%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-19.255M
-24.35%		-21.83M
-47.92%		-25.264M
-64.26%		-28.562M
-107.69%		-26.833M
-39.36%		-30.505M
-39.74%		-32.443M
-28.41%		-33.667M
-17.87%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

IMRX Yearly Revenue VS EstimatesIMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
IMRX Yearly EPS VS EstimatesIMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
5.42%
EPS Next 5 Year
9.49%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-26.85%
EBIT Next 5 Year
-22.09%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

IMMUNEERING CORP - CLASS A / IMRX Forecast FAQ

What is the price target for IMRX stock?

12 analysts have analysed IMRX and the average price target is 17.34 USD. This implies a price increase of 214.13% is expected in the next year compared to the current price of 5.52.

What are the consensus estimates for IMRX stock next earnings?

The consensus EPS estimate for the next earnings of IMMUNEERING CORP - CLASS A (IMRX) is -0.26 USD and the consensus revenue estimate is 0 USD.

Can you provide the consensus rating for IMMUNEERING CORP - CLASS A stock?

The consensus rating for IMMUNEERING CORP - CLASS A (IMRX) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.